Quantitative SPECT/CT Imaging of 177Lu with In Vivo Validation in Patients Undergoing Peptide Receptor Radionuclide Therapy

被引:42
|
作者
Sanders, J. C. [1 ,2 ]
Kuwert, T. [2 ]
Hornegger, J. [1 ]
Ritt, P. [1 ,2 ]
机构
[1] Univ Erlangen Nurnberg, Dept Comp Sci, Pattern Recognit Lab, D-91058 Erlangen, Germany
[2] Univ Erlangen Nurnberg, Univ Hosp Erlangen, Clin Nucl Med, D-91054 Erlangen, Germany
关键词
Quantitative SPECT; Lu-177]DOTATATE; Peptide receptor radionuclide therapy; Dosimetry; RESOLUTION; DOSIMETRY; ACCURACY; TUMORS; PET;
D O I
10.1007/s11307-014-0806-4
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The purpose of this study is to extend an established SPECT/CT quantitation protocol to Lu-177 and validate it in vivo using urine samples, thus providing a basis for 3D dosimetry of Lu-177 radiotherapy and improvement over current planar methods which improperly account for anatomical variations, attenuation, and overlapping organs. In our quantitation protocol, counts in images reconstructed using an ordered subset-expectation maximization algorithm are converted to kilobecquerels per milliliter using a calibration factor derived from a phantom experiment. While varying reconstruction parameters, we tracked the ratio of image to true activity concentration (recovery coefficient, RC) in hot spheres and a noise measure in a homogeneous region. The optimal parameter set was selected as the point where recovery in the largest three spheres (16, 8, and 4 ml) stagnated, while the noise continued to increase. Urine samples were collected following 12 SPECT/CT acquisitions of patients undergoing [Lu-177]DOTATATE therapy, and activity concentrations were measured in a well counter. Data was reconstructed using parameters chosen in the phantom experiment, and estimated activity concentration from the images was compared to the urine values to derive RCs. In phantom data, our chosen parameter set yielded RCs in 16, 8, and 4 ml spheres of 80.0, 74.1, and 64.5 %, respectively. For patients, the mean bladder RC was 96.1 +/- 13.2 % (range, 80.6-122.4 %), with a 95 % confidence interval between 88.6 and 103.6 %. The mean error of SPECT/CT concentrations was 10.1 +/- 8.3 % (range, -19.4-22.4 %). Our results show that quantitative Lu-177 SPECT/CT in vivo is feasible but could benefit from improved reconstruction methods. Quantifying bladder activity is analogous to determining the amount of activity in the kidneys, an important task in dosimetry, and our results provide a useful benchmark for future efforts.
引用
收藏
页码:585 / 593
页数:9
相关论文
共 50 条
  • [21] Quantitative accuracy of 177Lu SPECT imaging for molecular radiotherapy
    Mezzenga, Emilio
    D'Errico, Vincenzo
    D'Arienzo, Marco
    Strigari, Lidia
    Panagiota, Koutla
    Matteucci, Federica
    Severi, Stefano
    Paganelli, Giovanni
    Fenwick, Andrew
    Bianchini, David
    Marcocci, Francesco
    Sarnelli, Anna
    PLOS ONE, 2017, 12 (08):
  • [22] Evaluation of Template-based Partial Volume Correction Methods in 177Lu SPECT imaging for Dosimetry Improvement in Peptide Receptor Radionuclide Therapy
    Brolin, G.
    Gustafsson, J.
    Gleisner, K. Sjogreen
    Ljungberg, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S311 - S311
  • [23] Development of [177Lu]Lu-LNC1010 for peptide receptor radionuclide therapy of nasopharyngeal carcinoma
    Chen, Jianhao
    Pang, Yizhen
    Liao, Xiyi
    Zhou, Yangfan
    Luo, Qicong
    Wu, Hua
    Zuo, Changjing
    Zhang, Jingjing
    Lin, Qin
    Chen, Xiaoyuan
    Zhao, Liang
    Chen, Haojun
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 52 (01) : 247 - 259
  • [24] Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC
    Wehrmann, Christiane
    Senftleben, Stefan
    Zachert, Carolin
    Mueller, Dirk
    Baum, Richard P.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2007, 22 (03) : 406 - 416
  • [25] Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
    Staanum, Peter Frohlich
    Frellsen, Anders Floor
    Olesen, Marie Louise
    Iversen, Peter
    Arveschoug, Anne Kirstine
    EJNMMI PHYSICS, 2021, 8 (01)
  • [26] A Pipeline for Automated Voxel Dosimetry: Application in Patients with Multi-SPECT/CT Imaging After 177Lu-Peptide Receptor Radionuclide Therapy
    Dewaraja, Yuni K.
    Mirando, David M.
    Peterson, Avery B.
    Niedbala, Jeremy
    Millet, John D.
    Mikell, Justin K.
    Frey, Kirk A.
    Wong, Ka Kit
    Wilderman, Scott J.
    Nelson, Aaron S.
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (11) : 1665 - 1672
  • [27] Predictive Value of Asphericity in Pretherapeutic [111In]DTPA-Octreotide SPECT/CT for Response to Peptide Receptor Radionuclide Therapy with [177Lu]DOTATATE
    Wetz, Christoph
    Apostolova, I.
    Steffen, I. G.
    Hofheinz, F.
    Furth, C.
    Kupitz, D.
    Ruf, J.
    Venerito, M.
    Klose, S.
    Amthauer, Holger
    MOLECULAR IMAGING AND BIOLOGY, 2017, 19 (03) : 437 - 445
  • [28] Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
    Peter Frøhlich Staanum
    Anders Floor Frellsen
    Marie Louise Olesen
    Peter Iversen
    Anne Kirstine Arveschoug
    EJNMMI Physics, 8
  • [29] Quantitative SPECT/CT for Dosimetry of Peptide Receptor Radionuclide Therapy
    Kennedy, John
    Chicheportiche, Alexandre
    Keidar, Zohar
    SEMINARS IN NUCLEAR MEDICINE, 2022, 52 (02) : 229 - 242
  • [30] Predictive Value of Asphericity in Pretherapeutic [111In]DTPA-Octreotide SPECT/CT for Response to Peptide Receptor Radionuclide Therapy with [177Lu]DOTATATE
    Christoph Wetz
    I. Apostolova
    I. G. Steffen
    F. Hofheinz
    C. Furth
    D. Kupitz
    J. Ruf
    M. Venerito
    S. Klose
    Holger Amthauer
    Molecular Imaging and Biology, 2017, 19 : 437 - 445